OneSource Specialty Pharma Limited has successfully secured the renewal of its European Union Good Manufacturing Practices (EU-GMP) certification for its flagship Unit II manufacturing facility in Bengaluru. The company disclosed this regulatory milestone on April 17, 2026, under Regulation 30, following a comprehensive inspection conducted by a European regulatory authority.

Facility Details and Capabilities

The certified Unit II facility represents a cornerstone of OneSource's manufacturing operations, functioning as an integrated biologics manufacturing site. The facility demonstrates advanced capabilities across multiple specialized areas of pharmaceutical production.

Regulatory Significance

The EU-GMP certification renewal underscores OneSource Specialty Pharma's commitment to maintaining the highest standards of pharmaceutical manufacturing quality and regulatory compliance. This certification enables the company to continue manufacturing products that meet stringent European regulatory requirements for biologics and sterile injectable products.

The successful renewal process involved a thorough inspection by European regulatory authorities, validating the facility's adherence to Good Manufacturing Practices standards. This regulatory approval is particularly significant for biologics manufacturing, where stringent quality controls and manufacturing protocols are essential.

Manufacturing Excellence

Unit II's designation as a flagship facility reflects its strategic importance within OneSource's manufacturing network. The facility's integrated approach to biologics production, combining both drug-substance and drug-product manufacturing capabilities, positions the company to serve diverse pharmaceutical market segments.

The facility's specialized focus on drug-device combinations and sterile injectable products demonstrates OneSource's commitment to advanced pharmaceutical manufacturing technologies. These capabilities are increasingly important in the evolving pharmaceutical landscape, where complex drug delivery systems and sterile manufacturing processes are in high demand.

OneSource Specialty Pharma Limited has received an Environmental, Social and Governance (ESG) rating of 73 from NSE Sustainability Ratings & Analytics Limited for the financial year FY25. The company announced this development through a regulatory filing dated April 16, 2026, submitted under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

ESG Rating Details

The ESG rating assessment resulted in the following outcome for OneSource Specialty Pharma:

Independent Assessment Process

NSE Sustainability conducted this rating exercise independently, without any engagement from OneSource Specialty Pharma. The rating agency based its assessment entirely on information pertaining to FY25 that was available in the public domain. This approach demonstrates the objective nature of the evaluation process, as the company did not initiate or participate in requesting this ESG rating.

Regulatory Compliance

The intimation was made in accordance with SEBI Master Circular no. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was signed by Trisha A, who serves as the Compliance Officer and Company Secretary of OneSource Specialty Pharma Limited, with membership number A47635.

ESG Rating Significance

The 'Leader' category rating of 73 reflects OneSource Specialty Pharma's performance across environmental, social, and governance parameters. ESG ratings have become increasingly important for companies as investors and stakeholders place greater emphasis on sustainable business practices and corporate responsibility. The independent nature of this assessment by NSE Sustainability adds credibility to the rating outcome.